Side Effects from Tirzepatide: What the Clinical Evidence Actually Shows

What the SURMOUNT trials recorded about side effects

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity over 72 weeks and remains the primary source for tirzepatide's side-effect profile in the weight-management setting. Across all active doses, the most frequently reported adverse effects were nausea, diarrhoea, vomiting and constipation. Rates were dose-related (higher at 15 mg than at 5 mg) but the pattern was consistent: symptoms clustered around the start of treatment and around each dose step, then settled for most participants. Fewer than 5% of participants discontinued because of gastrointestinal side effects. That figure is worth holding onto when you read the listed side effects on a patient information leaflet. The NHS medicines page for tirzepatide puts those same effects in plain language: feeling sick, being sick, stomach pain, indigestion, burping, wind, reflux, headache, dizziness, fatigue and injection-site reactions. None of that is rare or surprising, it reflects how the medicine works, slowing the movement of food through the stomach and interacting with gut-hormone receptors involved in appetite. It does not mean everyone experiences every item on that list.

Side effects that need prompt medical attention

Most tirzepatide side effects are inconvenient rather than dangerous. A few are not. In January 2026 the MHRA issued a Drug Safety Update on GLP-1 receptor agonist medicines highlighting acute pancreatitis as a known, infrequent but potentially serious risk. The signal to act on is severe stomach pain that does not ease and may spread toward the back, with or without vomiting. If that happens, stop taking tirzepatide and seek urgent medical help rather than waiting for it to pass. Other symptoms to take seriously without delay include signs of an allergic reaction (swelling of the face, lips or throat; difficulty breathing), significant dehydration following prolonged vomiting or diarrhoea, sudden changes in vision, and symptoms that suggest gallbladder problems such as sudden sharp pain in the upper right abdomen. People with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take tirzepatide; this is assessed during the prescribing consultation. Patients can report any suspected adverse effect (including effects not listed in the leaflet) to the MHRA Yellow Card scheme. For changes in mood or mental health that emerge after starting tirzepatide, the same principle applies: report them and speak to your prescriber sooner rather than later.

Everyday side effects and what tends to help

For the majority of people, managing tirzepatide side effects is a practical question rather than a medical crisis. Nausea is the most commonly reported complaint, and our prescribers hear the same practical questions most weeks: is it better to inject at night so you sleep through the worst of it, and does it matter which day of the week you choose? The honest answer is that individual responses vary. Some people find an evening injection easier; others prefer a morning dose on a day they can rest, though the medicine itself doesn't change. What is consistent in the evidence is that eating smaller portions, avoiding rich or fatty food in the hours around the injection, and drinking enough water all make a measurable difference to GI tolerability. The titration schedule exists precisely for this reason: the 2.5 mg starting dose is there to let your body adjust, not because it is the dose doing the main work therapeutically. Stepping up too quickly when a dose feels comfortable can bring the nausea back. Any changes to your titration timing should be agreed with your prescriber. A short note on timing: if you're ordering around a bank holiday, a Monday delivery after a Friday dispatch won't arrive until Tuesday, worth factoring in so you don't run short mid-week and feel pressure to adjust your injection schedule yourself. The first day after your initial injection tends to prompt the most questions, and there is separate guidance available if that's where you are. Less commonly discussed but worth knowing: some people report changes in vision during treatment; this is something prescribers ask about specifically, and it should always be mentioned at your next clinical check-in.

How suitability and risk are assessed before treatment starts

Tirzepatide is a prescription-only medicine under the Human Medicines Regulations, it cannot legally be supplied without a clinical assessment. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber who checks your medical history, any existing conditions, and any other medicines you take before deciding whether tirzepatide is appropriate for you, and our tirzepatide side effects guidance gives a fuller picture of what that clinical review covers. This is the mechanism that makes the safety data above meaningful: the SURMOUNT trials enrolled people who met specific criteria, and prescribing outside those criteria changes the risk calculation. For a full overview of tirzepatide (how it works, who it is licensed for, and what the NICE eligibility thresholds look like) the Mounjaro overview page sets that out. The related side-effect discussion that specifically covers the Mounjaro brand name is on the Mounjaro side effects page. If you have questions before starting or are already on treatment and want to discuss something, our prescribers are available through aftercare support seven days a week. To find out whether tirzepatide is suitable for you, check your eligibility with a free consultation.